west coast bu tour
corona impact far manag
part west coast bu virtual year host investor call
illumina cfo ad ir jacqui ross much call focus on-going
coronaviru outbreak potenti impact somewhat surprisingli mr
samad note far compani seen minimum disrupt albeit situat
fluid china specif abl manag mnfctr
presenc littl exposur local supplier focu simpli maintain
product flow distribut channel europ us sale forc continu
perform site visit in-person virtual part custom behavior
ilmn busi hasnt realli chang recent week howev think given
rapidli deterior situat eu us lab contempl temporari
shutdown ie broad institut ceas non-crit lab activ least
sever week popul sequenc popseq project still yet launch
there downsid risk outlook uncertainti overhang
reiter under-perform rate lower po dcf-
base valuat move lower higher wacc earlier given volatil
mani move part
move beyond call focus variou driver play
attempt reacceler growth trough move piec
focu fade dtc headwind popseq sequenc
consum strength mr samad emphas
expect see minim novaseq cannib uptak come primarili
exist nextseq user look higher throughput popseq key
swing factor appear us temporari paus in-person
appoint event increment project uk biobank
expect sampl year current full-scal product mode
genom england/nh sampl start later year competit
sequenc landscap becom activ last year believ
limit competit risk although think price power may hit
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart san diego california
consum servic genet analysi
compani proprietari product servic
use research broad spectrum
scientif activ gain greater understand
genet variat biolog function
tool play import role
develop creation molecular test
posit technolog
market posit overal genom
market see near-term risk tie execut
visibl custom time demand
pend acquisit macro
competit risk
price object base dcf analysi assum wacc
approxim termin growth rate po correspond
approxim revenu estim roughli ep estim
consid justifi given near-term question certain pocket
busi relat execut
downsid risk po weaker-than-expect academ fund lower
consum pull-through competit within genet analysi market regulatori
reimburs uncertainti clinic sequenc market acquisit relat
integr issu grow concern data privaci slower-than-expect uptak
new product
upsid risk po strong recoveri instrument placement overal
sequenc demand new product cycl stabilization/recoveri direct-to-
consum dtc market increas spend high-throughput custom better
clinic reimbursement/market penetr acquisit compani
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
